Vaccine for Prevention herpetic infections | Vitagerpavak lyophilisate d / pr-r for intravenous skin injected 0.3 ml vials of 5 pcs.

Product form

Lyophilisate for solution for intradermal administration solution

Packaging

5 vials.

Pharmacological action

The vaccine stimulates the cellular mechanisms of human resistance to herpes simplex virus types I and II.

Indications

Vitagerpavak vaccine is intended for the prevention of recurrence of herpes infection.

Contraindications

Herpetic infection in the active stage (relapse). Vaccination is carried out not earlier, than 5 days after the disappearance of clinical manifestations with ophthalmic herpes - not earlier than 1 month.

Acute infectious and non-communicable diseases.

Chronic diseases at the stage of exacerbation or decompensation.

Malignant neoplasms.

Pregnancy.

Allergy to gentamicin and other aminoglycoside antibiotics.

Use during pregnancy and lactation

Contraindication - pregnancy.

Special instructions

Vaccination is carried out in medical institutions (hospital, dispensary, clinic) under the supervision of a physician.

Vaccination is carried out in remission, not earlier than 5 days after the complete disappearance of the clinical manifestations of herpes infection.

If more local and general reactions occur or if the main process worsens, vaccination should be discontinued. Vaccination can be continued after the clinical manifestations of the general reaction to the vaccine have completely disappeared.

All cases of more pronounced local and general reactions in a patient should be examined by a doctor and recorded in the appropriate document.

The dissolved preparation should be a slightly opalescent pink liquid.

The drug is not suitable for use in bottles with impaired integrity, labeling, color change, expired Expiration, or improper storage.

Dissolved vaccine is not to be stored.

Opening the bottle, dissolving the drug and the vaccination procedure is carried out with strict adherence to aseptic rules.

Composition

Contains gentamicin sulfate no more than 40 ?g / ml,

stabilizer - sucrose at a final concentration of 0.075 g / ml and gelatose at a final concentration of 0.01 g / ml,

formaldehyde at a final concentration of 200 ?g / ml.

Vitagerpavak vaccine is an inactivated herpes simplex virus of antigenic types I and II, obtained by reproduction in Vero B cell culture,

lyophilized,

amorphous mass from yellow to pink,

is hygroscopic.

Dosage and administration

Vaccination is carried out in medical institutions (hospital, dispensary, clinic) under the supervision of a physician. The vaccine is used in remission, not earlier, than 5 days after the complete disappearance of the clinical manifestations of herpes infection.

The drug is administered intradermally into the inner surface of the forearm using a syringe in a single dose of 0.2 ml (control - the formation of a "lemon peel").

The vaccination course for herpetic infections of the skin and mucous membranes consists of 5 injections, which are carried out at intervals of 7 days.

Patients with complicated herpetic infection 2nd and subsequent injections are repeated with an interval of 10 days.

After 6 months, a second course of vaccination is carried out (5 injections).

Side effects

Local reaction: flushing of the skin with a diameter of up to 2 cm during the first day and weak short-term burning - these are normal body reactions to the introduction of the drug.

General reaction: slight fever, weakness, passing without treatment.

If more local and general reactions occur or if the main process worsens, vaccination should be discontinued.

Vaccination can be continued after the clinical manifestations of the general reaction to the vaccine have completely disappeared.

Storage conditions

Store in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 8 РC, out of the reach of children.

Expiration

2 years.

Dosage form

solution for injection

Vitafarma, Russia